Acclaimed Cardiology Expert Dr. Peter Libby To Keynote 19th Annual CMHC, Revolutionize Atherosclerosis Care
22 mai 2024 11h00 HE
|
Cardiometabolic Health Congress
Boca Raton, FL, May 22, 2024 (GLOBE NEWSWIRE) -- The Cardiometabolic Health Congress (CMHC) is proud to announce that one of the foremost authorities in atherosclerosis, Peter Libby, MD, will...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
14 mai 2024 07h57 HE
|
ZyVersa Therapeutics
To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
04 avr. 2024 07h57 HE
|
ZyVersa Therapeutics
Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14 mars 2024 07h57 HE
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
06 déc. 2023 07h20 HE
|
ZyVersa Therapeutics
AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
Endothelial Dysfunction Market to Reach $2.58Bn, Globally, by 2028 at 4.4% CAGR with Hypertension Segment Driving Growth During 2022-2028 | Report by The Insight Partners
11 août 2023 06h41 HE
|
The Insight Partners
Pune, India, Aug. 11, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on “Endothelial Dysfunction Market Size Report & Share, Forecast to 2028 – COVID-19 Impact and...
Curcumin Market Growth Analysis Report - $135.5 Million, Globally, by 2028 at 9.1% CAGR – Comprehensive Study by The Insight Partners
20 mars 2023 10h54 HE
|
The Insight Partners
New York, March 20, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Curcumin Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...
Kizoo Portfolio Company Underdog Closes $10M Financing Round
23 sept. 2021 07h00 HE
|
KIZOO Technology Capital GmbH
MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital....
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
08 sept. 2021 11h00 HE
|
Underdog Pharmaceuticals Inc.
MOUNTAIN VIEW, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related...
Inflation Devices Market Size to Reach Valuation of $770 million by 2026 | AMR
15 févr. 2021 10h00 HE
|
Allied Market Research
Portland, OR, Feb. 15, 2021 (GLOBE NEWSWIRE) -- According to the report, the global inflation devices market was valued at $517 million in 2018, and is expected to reach $770 million by 2026,...